DGAP-Adhoc: Biotest AG: Biotest increases earnings after taxes by 38.5%

| Source: EQS Group AG
Biotest AG  / Key word(s): Preliminary Results

20.02.2014 10:30

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Biotest increases earnings after taxes by 38.5%

Dreieich, 20. February 2014. According to preliminary and unaudited
figures, the Biotest Group recorded earnings after tax (EAT) of EUR 32.0
million, an increase from EUR 23.1 million in 2012 by 38.5%. Earnings
before taxes (EBT) increased by 31.0% to EUR 47.8 million (previous year
result EUR 36.5 million). The main factors for this profit increase were
significant higher sales in the US and in Asia.

The Group's earnings before interest and tax (EBIT) have increased
disproportionately to sales by 20.4%. to EUR 53.8 million compared to the
previous year's EBIT of EUR 44.7 million. As a result the EBIT margin
increased from 10.2% to 10.7%.

In the financial year 2013 Biotest reached sales of EUR 500.8 million, an
increase of 13.8% compared to the previous year (EUR 440.0 million).

Biotest will publish final results for the Financial Year 2013 and the
annual report on March 25th, 2014. The Annual General Meeting of Biotest AG
will take place on May 7th, 2014 in Frankfurt a.M.

Biotest Aktiengesellschaft
The Executive Management Board

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich


This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

20.02.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement                             DGAP News-Service